Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Oncology
Roche, Synlogic team for immunotherapy trial
by Lisa Jarvis
June 1, 2019
| A version of this story appeared in
Volume 97, Issue 22
Roche and Synlogic have teamed up to test combining two immune-modulating cancer treatments: Roche’s PD-L1 checkpoint inhibitor Tecentriq and Synlogic’s SYNB1891, a strain of Escherichia coli engineered to express an agonist of STING, part of the innate immune system that drives the production of inflammatory proteins that, in turn, cause the adaptive immune system to kick into gear. Synlogic says it will ask the US Food and Drug Administration for the green light to begin human studies of SYNB1891 in the second half of this year.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X